|
Sep 27
|
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
|
|
Sep 10
|
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
|
|
Sep 6
|
Aclarion Added to PRISM Emerging Medical Devices Index
|
|
Sep 5
|
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
|
|
Jun 26
|
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
|
|
Jun 25
|
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
|
|
Jan 29
|
Thinking about buying stock in Spectral AI, Applied UV, Adobe, BigBear.ai, or Aclarion?
|
|
Nov 27
|
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
|
|
Nov 8
|
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
|
|
Nov 6
|
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
|
|
Aug 25
|
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
|
|
May 23
|
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
|
|
May 23
|
Aclarion, Inc. Announces Delayed 10-Q Filing
|
|
May 19
|
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
|